Sorrento Therapeutics Announces the Formation of Sorrento Therapeutics Mexico for Commercialization of COVI-STIX and Development of Sorrento’s Portfolio of COVID-19 Products in Mexico and Parts of Latin America Sorrento Therapeutics has established a Subsidiary Company in Mexico - Sorrento Therapeutics Mexico.Sorrento’s Mexican importer of record has received an initial importation permit from Mexico...

Sorrento Receives EUA Approval and Import License From Mexico Authority COFEPRIS For COVI-STIX™ (COVID-19 Virus Rapid Antigen Detection Test) and Plans Product Launch With Initial Shipments in July Sorrento received official EUA registration and product import license: COFEPRIS EUA registration number “OFICIO: CAS/10720/2021”.Sorrento is establishing its “Sorrento Mexico Ltd” subsidiary to...

Sorrento Announces Addition of COVI-STIX™ (Covid-19 Virus Rapid Antigen Detection Test) to the Official Mexican Government List of Emergency Use Approved Point of Care Rapid Antigen Tests COVI-STIX has been added to the official government list of point of care rapid antigen tests useful for the detection of SARS-CoV-2 in Mexico...

Sorrento Announces the Submission of a Marketing Authorization Application to COFEPRIS (Mexico) for COVI-STIX™ Rapid Detection Test of SARS-CoV-2 Viral Antigen SAN DIEGO, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that a Marketing Authorization Application has been submitted by its agents in...

Sorrento Receives Licensure From the State of California for Clinical Testing Laboratory (CLIA) Allowing for Clinical Sample Testing Sorrento receives Clinical Laboratory Improvement Amendments (CLIA) license from the State of California for clinical sample testingSorrento intends to initially offer three diagnostic tests for...